百奥泰：公司正在加紧准备BAT8006临床项目 估计本月开始入组受试者

Core Viewpoint - The company is accelerating preparations for the BAT8006 clinical project, with an estimated start for subject enrollment this month [1] Group 1: Clinical Development Plans - The company aims to obtain approval for BAT2206 in major markets (China, the US, and Europe) in the second half of this year and early next year [1] - The unblinding date for the first III phase indication study of BAT5906 for wAMD is set for the end of Q2 2025 [1] - Ongoing clinical trials for DME are in progress, with plans for registration clinical studies targeting CNV and CRVO in the preparatory stage [1] Group 2: Product Development and Collaborations - Development of subcutaneous tocilizumab and collaboration for tocilizumab in Europe are progressing [1] - The company is working to expedite the sales of already approved intravenous administration in Europe [1]